3,632
edits
TYK23: Difference between revisions
Jump to navigation
Jump to search
no edit summary
m (1 revision imported) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
The unique advantage of rocuronium over other intermediate duration non-depolarizing muscle relaxants (NDMR) is which of the following? | The unique advantage of rocuronium over other intermediate duration non-depolarizing muscle relaxants (NDMR) is which of the following? | ||
| Line 13: | Line 12: | ||
E. Lack of potentiation with aminoglycoside antibiotics | E. Lack of potentiation with aminoglycoside antibiotics | ||
<div class="mw-customtoggle-TYK_Answer" style="text-align: right; color:#0000ff">Click for Answer</div> | |||
<div class="mw-collapsible- | <div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-TYK_Answer"> | ||
==Answer== | ==Answer== | ||
The answer is C. The first two letters of the name rocuronium stands for '''rapid onset'''. Of the intermediate duration nondepolarizing muscle relaxants, it has the most rapid onset of action at clinical dosages. Rocuronium has a similar duration of action to vecuronium, | The answer is C. The first two letters of the name rocuronium stands for '''rapid onset'''. Of the intermediate duration nondepolarizing muscle relaxants, it has the most rapid onset of action at clinical dosages. Rocuronium has a similar duration of action to vecuronium, | ||
atracurium, and cisatracurium. At an ED95 dose (0.3 mg/kg), the onset time is 1.5 to 3 minutes, whereas with | atracurium, and cisatracurium. At an ED95 dose (0.3 mg/kg), the onset time is 1.5 to 3 minutes, whereas with | ||
| Line 27: | Line 25: | ||
[http://www.drugbank.ca/drugs/DB00728 Rocuronium (DrugBank)] | [http://www.drugbank.ca/drugs/DB00728 Rocuronium (DrugBank)] | ||
==Keywords== | ==Keywords== | ||
</div> | </div> | ||
---- | ---- | ||
---- | ---- | ||